Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.792
+0.082 (11.56%)
Apr 28, 2026, 2:22 PM EST

BCLI Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
5.787.0410.6910.879.3
Upgrade
Research & Development
4.184.6510.7513.9615.24
Upgrade
Operating Expenses
9.9511.6921.4424.8224.54
Upgrade
Operating Income
-9.95-11.69-21.44-24.82-24.54
Upgrade
Interest Expense
-0.53-0.08-0.28--
Upgrade
Interest & Investment Income
---0.550.08
Upgrade
Other Non Operating Income (Expenses)
0.180.154.53--
Upgrade
Pretax Income
-10.31-11.62-17.19-24.28-24.46
Upgrade
Net Income
-10.31-11.62-17.19-24.28-24.46
Upgrade
Net Income to Common
-10.31-11.62-17.19-24.28-24.46
Upgrade
Shares Outstanding (Basic)
95322
Upgrade
Shares Outstanding (Diluted)
95322
Upgrade
Shares Change (YoY)
84.58%74.87%17.99%0.91%21.22%
Upgrade
EPS (Basic)
-1.11-2.31-5.99-9.97-10.14
Upgrade
EPS (Diluted)
-1.11-2.31-5.99-9.97-10.20
Upgrade
Free Cash Flow
-6.98-9.09-20.48-19.35-26.6
Upgrade
Free Cash Flow Per Share
-0.75-1.81-7.13-7.95-11.03
Upgrade
EBITDA
-9.75-11.45-21.17-24.54-24.28
Upgrade
D&A For EBITDA
0.20.240.270.290.26
Upgrade
EBIT
-9.95-11.69-21.44-24.82-24.54
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.